Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
Purple Biotech Ltd., a foreign private issuer based in Rehovot, Israel, filed this Form 6-K on October 20, 2025. The filing serves to distribute a press release regarding a regulatory notification received from the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
The material event disclosed is the receipt of a notification from Nasdaq indicating that the Company's common stock has failed to meet the minimum bid price requirement for continued listing.
Outlook, Risks, and Management Commentary
The filing references a press release (Exhibit 99.1) detailing the Nasdaq notification. While the text confirms the receipt of the notice, it does not include specific management commentary, future guidance, or a detailed risk assessment within the body of this summary document. The primary risk highlighted is the potential delisting or loss of compliance status with Nasdaq listing standards.
Investor Verification Checklist
- Verify the current trading price of Purple Biotech Ltd. common stock against the Nasdaq minimum bid price requirement.
- Review the full text of the attached press release (Exhibit 99.1) for the Company's proposed compliance plan or timeline.
- Check for any subsequent filings regarding the Company's response to the Nasdaq notification.
- Confirm the Company's current cash position to assess its ability to fund operations while addressing the listing deficiency.